Department of Neurology, University of California, San Francisco, 350 Parnassus Avenue, 304 A, San Francisco, CA, 94117, USA.
Department of Neurology, Oregon Health and Science University, Portland, OR, USA.
Curr Treat Options Neurol. 2016 Jan;18(1):1. doi: 10.1007/s11940-015-0385-y.
Several randomized trials have demonstrated potential benefit of cannabis derivatives in the symptomatic treatment of multiple sclerosis (MS) patients. These provide class 1 and 2 evidence for cannabinoid product use for spasticity and pain in these patients. The precise best ratio or doses are not yet clear. The safety and potential long-term effects of these products on cognitive function in people with MS have not been evaluated. Since short-term memory and processing speed can be significantly impaired in many people with MS, the concern of potential cognitive impairment related to cannabis products needs consideration in clinical care and should be addressed in longer, prospective studies.
几项随机试验表明，大麻衍生物在多发性硬化症（MS）患者的症状治疗中有潜在益处。这些为大麻素产品在这些患者的痉挛和疼痛治疗中的应用提供了 1 类和 2 类证据。确切的最佳比例或剂量尚不清楚。这些产品对 MS 患者认知功能的安全性和潜在长期影响尚未得到评估。由于许多 MS 患者的短期记忆和处理速度可能会受到严重影响，因此需要在临床护理中考虑与大麻产品相关的潜在认知障碍的可能性，并在更长的前瞻性研究中加以解决。
